Salix Pharmaceuticals and Mitsubishi Tanabe Pharma Corporation, a subsidiary of Bausch Health, have entered an exclusive licensing agreement to develop and commercialize amiselimod, a late-stage oral compound that targets the sphingosine 1-phosphate (S1P) receptor, to treat inflammatory bowel disease, according to a company press release.
“For patients living with IBD, amiselimod represents an opportunity to develop an oral, non-immunogenic treatment as an alternative to biologics and other available therapies,” Mark McKenna, president of Salix Pharmaceuticals, said in the release.

Source link